Inhibiting HSP90 represents an appealing approach to combined therapy, as there have been numerous reports indicating that HSP90 inhibitors can induce significant and lethal damage to tumor cells when used in binding with X-ray radiation therapy (Segawa et al., 2014). Here, HSP90AB1 is linked to neoplasm.